<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="55608"><DrugName>seladelpar lysine</DrugName><DrugNamesKey><Name id="43084678">seladelpar</Name><Name id="43117501">seladelpar lysine</Name></DrugNamesKey><DrugSynonyms><Name><Value>RWJ-800025</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MBX-8025</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MBX-8025 L-lysine dihydrate</Value></Name><Name><Value>seladelpar</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>seladelpar L-lysine dihydrate</Value></Name><Name><Value>seladelpar lysine</Value><Types><Type>USAN</Type></Types></Name><Name><Value>MBX-8025 lysine</Value></Name><Name><Value>851528-79-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>928821-40-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17580">Ortho-McNeil Inc</CompanyOriginator><CompaniesPrimary><Company id="18199">CymaBay Therapeutics Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="17580">Ortho-McNeil Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55608" type="Drug"><TargetEntity id="429263" type="siDrug"></TargetEntity><TargetEntity id="441097" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="17580" type="Company"><TargetEntity id="5000265442" type="organizationId">Janssen Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="18199" type="Company"><TargetEntity id="4297588727" type="organizationId">Cymabay Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1995" type="ciIndication"><TargetEntity id="K74.3" type="ICD10"></TargetEntity><TargetEntity id="10004661" type="MEDDRA"></TargetEntity><TargetEntity id="186" type="ORPHANET"></TargetEntity><TargetEntity id="422" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2477" type="ciIndication"><TargetEntity id="D015209" type="MeSH"></TargetEntity><TargetEntity id="171" type="ORPHANET"></TargetEntity><TargetEntity id="-1102157171" type="omicsDisease"></TargetEntity><TargetEntity id="436" type="siCondition"></TargetEntity><TargetEntity id="5485" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2637" type="ciIndication"><TargetEntity id="K75.81" type="ICD10"></TargetEntity><TargetEntity id="1412" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3204" type="ciIndication"><TargetEntity id="970" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3294" type="ciIndication"><TargetEntity id="E88.81" type="ICD10"></TargetEntity><TargetEntity id="10052066" type="MEDDRA"></TargetEntity><TargetEntity id="D024821" type="MeSH"></TargetEntity><TargetEntity id="-65628361" type="omicsDisease"></TargetEntity><TargetEntity id="512" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3971" type="Action"><TargetEntity id="894" type="Mechanism">PPARdelta Agonists</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-01595" type="ciTarget"><TargetEntity id="115390278054673" type="siTarget">Peroxisome proliferator-activated receptor delta</TargetEntity><TargetEntity id="-1824428328" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1995">Primary biliary cholangitis</Indication><Indication id="2477">Primary sclerosing cholangitis</Indication><Indication id="2637">Non-alcoholic steatohepatitis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3204">Familial hypercholesterolemia</Indication><Indication id="3294">Metabolic syndrome X</Indication><Indication id="584">Lipid metabolism disorder</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="3971">PPAR delta agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology></Technologies><LastModificationDate>2019-06-26T07:09:18.000Z</LastModificationDate><ChangeDateLast>2019-06-26T00:00:00.000Z</ChangeDateLast><AddedDate>2006-06-27T15:07:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18199" linkType="Company"&gt;CymaBay Therapeutics&lt;/ulink&gt; (formerly known as &lt;ulink linkID="18199" linkType="Company"&gt;Metabolex&lt;/ulink&gt;), under license from &lt;ulink linkID="17580" linkType="Company"&gt;Ortho-McNeil&lt;/ulink&gt;, is developing the oral PPAR-delta agonist seladelpar (MBX-8025, RWJ-800025), as the L-lysine dihydrate salt, for the potential treatment of primary biliary cirrhosis/cholangitis (PBC)     [&lt;ulink linkID="675598" linkType="Reference"&gt;675598&lt;/ulink&gt;], [&lt;ulink linkID="1488187" linkType="Reference"&gt;1488187&lt;/ulink&gt;], [&lt;ulink linkID="1712050" linkType="Reference"&gt;1712050&lt;/ulink&gt;], [&lt;ulink linkID="1996771" linkType="Reference"&gt;1996771&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;In December 2017, a phase III trial was initiated in patients with PBC [&lt;ulink linkID="1996771" linkType="Reference"&gt;1996771&lt;/ulink&gt;]; in October 2018, a registrational phase III  study in PBC began [&lt;ulink linkID="2088487" linkType="Reference"&gt;2088487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Seladelpar is also being developed in non-alcoholic steatohepatitisÂ (NASH) and primary sclerosing cholangitis (PSC). In May 2018, a phase IIb study was initiated for NASH [&lt;ulink linkID="2031714" linkType="Reference"&gt;2031714&lt;/ulink&gt;]; in June 2019, negative topline data were reported  [&lt;ulink linkID="2161555" linkType="Reference"&gt;2161555&lt;/ulink&gt;]. In June 2019, the drug was listed as being in phase I development for PSC [&lt;ulink linkID="2158123" linkType="Reference"&gt;2158123&lt;/ulink&gt;]; at that time, the FDA approved an IND for the treatment of PSC. At that time, a phase II study in patients with PSC was planned to initiate in 3Q19 [&lt;ulink linkID="2165814" linkType="Reference"&gt;2165814&lt;/ulink&gt;], [&lt;ulink linkID="2158123" linkType="Reference"&gt;2158123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Metabolex was developing  seladelpar for type  2 diabetes,  dyslipidemia and homozygous familial hypercholesterolemia (HoFH). In June 2006, the drug was in phase I development for diabetes [&lt;ulink linkID="675598" linkType="Reference"&gt;675598&lt;/ulink&gt;]; however, in April 2011, no further development was reported for that indication  [&lt;ulink linkID="1186675" linkType="Reference"&gt;1186675&lt;/ulink&gt;]. In April 2015, phase II HoFH trial was  initiated [&lt;ulink linkID="1653819" linkType="Reference"&gt;1653819&lt;/ulink&gt;], [&lt;ulink linkID="1750890" linkType="Reference"&gt;1750890&lt;/ulink&gt;]; in March 2016, top-line results were reported [&lt;ulink linkID="1744679" linkType="Reference"&gt;1744679&lt;/ulink&gt;]; however, no further development has since been reported. In September 2007, a phase II trial for dyslipidemia, insulin-resistance and obesity was initiated [&lt;ulink linkID="833111" linkType="Reference"&gt;833111&lt;/ulink&gt;]; in November 2008, results were presented   [&lt;ulink linkID="964506" linkType="Reference"&gt;964506&lt;/ulink&gt;]; in April 2011,  phase II development for dyslipidemia, and development for metabolic syndrome was ongoing  [&lt;ulink linkID="1186675" linkType="Reference"&gt;1186675&lt;/ulink&gt;]; however, no further development has since been reported. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In March 2015, the US FDA granted an Orphan Drug Designation to seladelpar L-lysine dihydrate, for the treatment of HoFH [&lt;ulink linkID="1644945" linkType="Reference"&gt;1644945&lt;/ulink&gt;], [&lt;ulink linkID="1645775" linkType="Reference"&gt;1645775&lt;/ulink&gt;]. In April 2015, the FDA granted Orphan designation for the treatment of Frederickson Type I or V hyperlipoproteinemia [&lt;ulink linkID="1652799" linkType="Reference"&gt;1652799&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2016, the FDA granted the drug Orphan designation for the treatment of primary biliary cholangitis [&lt;ulink linkID="1871725" linkType="Reference"&gt;1871725&lt;/ulink&gt;]. In February 2019, the US FDA granted the drug Breakthrough Therapy designation for the treatment of early stage PBC in combination with ursodeoxycholic acid (UDCA)  in adult patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA [&lt;ulink linkID="2120303" linkType="Reference"&gt;2120303&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2017, the EMA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for Orphan drug designation of seladelpar for treatment of PBC [&lt;ulink linkID="1960906" linkType="Reference"&gt;1960906&lt;/ulink&gt;], [&lt;ulink linkID="1965438" linkType="Reference"&gt;1965438&lt;/ulink&gt;]; in October 2017, the Orphan designation was granted [&lt;ulink linkID="1987727" linkType="Reference"&gt;1987727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, the EMA granted theÂ PRIorityÂ MEdicine (PRIME) designationÂ to MBX-8025 for the treatment of PBCÂ [&lt;ulink linkID="1865233" linkType="Reference"&gt;1865233&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Primary biliary cirrhosis/cholangitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In July 2018, a randomized, double-blind, placebo-controlled, parallel assigned, phase III study (&lt;ulink linkID="347945" linkType="Protocol"&gt;NCT03602560&lt;/ulink&gt;; CB8025-31735; ENHANCE) was planned to evaluate the safety and efficacy of seladelpar in patients (expected n =  240) with PBC and an inadequate response to or intolerance to  UDCA and also to assess the safety and effect on cholestasis with two seladelpar regimens over 52 weeks of treatment when compared to placebo, effect on normalization of alkaline phosphatase (AP) levels and effect  on pruritus. The primary objective measure include composite endpoint of AP levels and total bilirubin. At that time, the trial was expected to complete in December 2021 [&lt;ulink linkID="2058841" linkType="Reference"&gt;2058841&lt;/ulink&gt;]. In October 2018, the trial was initiated [&lt;ulink linkID="2088487" linkType="Reference"&gt;2088487&lt;/ulink&gt;]. By December 2018, the study was expected to be fully enrolled by the end of 2019 and the 52-week treatment period was expected to complete by the end of 2020 [&lt;ulink linkID="2124631" linkType="Reference"&gt;2124631&lt;/ulink&gt;].Â In May 2019, top-line data from ENHANCE tiral were expected in 2021 [&lt;ulink linkID="2149700" linkType="Reference"&gt;2149700&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, the company was planning to initiate a phase III trial for PBC [&lt;ulink linkID="1953838" linkType="Reference"&gt;1953838&lt;/ulink&gt;].  In December 2017, an interventional, non-randomized, parallel assignment, open label, long-term extension phase II/III study (&lt;ulink linkID="315032" linkType="Protocol"&gt;NCT03301506&lt;/ulink&gt;; CB8025-31731) was initiated in the US, Canada, Germany and the UK to evaluate the safety and tolerability of seladelpar in patients (expected n= 356) with primary biliary cirrhosis  who had completed the phase II (&lt;ulink linkID="278730" linkType="Protocol"&gt;NCT02955602&lt;/ulink&gt;) low dose seladelpar study [&lt;ulink linkID="1996771" linkType="Reference"&gt;1996771&lt;/ulink&gt;]. In January 2018, first patients were enrolled in the trial and would provide additional long-term safety and efficacy data [&lt;ulink linkID="1996015" linkType="Reference"&gt;1996015&lt;/ulink&gt;]. In October 2018, the trial was expected to complete in 2022 [&lt;ulink linkID="1996771" linkType="Reference"&gt;1996771&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2017, pooled retrospective analysis data from two clinical studies (&lt;ulink linkID="246436" linkType="Protocol"&gt;NCT02609048&lt;/ulink&gt; and &lt;ulink linkID="278730" linkType="Protocol"&gt;NCT02955602&lt;/ulink&gt;) which evaluated the efficacy of seladelpar in patients with PBC were presented at the AASLD's Liver Meeting 2017 in Washington DC. Patients in both studies received seladelpar (5, 10, 50 or 200 mg/daily) or placebo. At week 2 and 4, pruritus visual analog scale (VAS) and 5-D itch severity was analyzed in 65 and 56 patients, respectively. At week 2 and 4, in patients with pruritus who used 5-D itch, concordance with VAS at baseline was 84 and 82%, respectively. In PBC patients a reasonable correlation was observed for severity of pruritus using VAS and 5-D itch [&lt;ulink linkID="1973257" linkType="Reference"&gt;1973257&lt;/ulink&gt;], [&lt;ulink linkID="1996772" linkType="Reference"&gt;1996772&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, a lower dose phase II study   for  	primary biliary cholangitis was expected by the end of 2016 [&lt;ulink linkID="1787003" linkType="Reference"&gt;1787003&lt;/ulink&gt;]. In December 2016, the 8-week, open-label, phase II study was initiated in PBC patients (expected n = 36). The study was to enroll patients in the US, UK, Germany and Canada, and include  26-week extension part   [&lt;ulink linkID="1883297" linkType="Reference"&gt;1883297&lt;/ulink&gt;]. In March 2017, interim data from the ongoing trial were expected  in the third quarter of 2017  [&lt;ulink linkID="1912979" linkType="Reference"&gt;1912979&lt;/ulink&gt;]. In April 2017, it was reported at 52nd EASL International Liver Congress in Amsterdam, the Netherlands that a phase II study (&lt;ulink linkID="278730" linkType="Protocol"&gt;NCT02955602&lt;/ulink&gt;; 2016-002996-91) was ongoing to explore lower doses [&lt;ulink linkID="1919606" linkType="Reference"&gt;1919606&lt;/ulink&gt;]. In July 2017, interim data from the first 24 patients were reported. Data demonstrated that, after 12 weeks of treatment, there was 39% and 45% of reduction of alkaline phosphatase (AP) levels for the 5 mg and 10 mg groups, respectively. AP values less than 1.67 times the upper limit of normal were observed in 45% of patients in the 5 mg and 82% of patients in the 10 mg dose groups. Reductions in other liver markers of cholestasis including gamma glutamyl transferase and total bilirubin and mean transaminase levels were also observed. The drug improved metabolic and inflammatory markers with patients experiencing decreases in low-density lipoprotein-C and high sensitivity C-reactive protein. At that time, the FDA accepted to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses [&lt;ulink linkID="1945698" linkType="Reference"&gt;1945698&lt;/ulink&gt;]. In October 2017, results were presented at the  The Liver Meeting hosted by the American Association for the Study of Liver Disease (AASLD) held in  Washington, DC [&lt;ulink linkID="1980035" linkType="Reference"&gt;1980035&lt;/ulink&gt;]. In April 2018, further clinical data were presented at 53rd EASL International Liver Congress in Paris, France. The PK parameters including Cmax (ng/ml), Tmax (h) and AUC (0 to 24) (ng.h/ml) were 25, 1.5 and 169 (2 mg), 55, 3.0 and 564 (5 mg) and 140, 5.7 and 1111 (10 mg), respectively, on day 1, whereas, 29, 1.0 and 267 (2 mg), 68, 2.8 and 831 (5 mg) and 142, 2.9 and 1387 (10 mg), respectively, at week 2. In PBC patients, seladelpar was found to be absorbed rapidly and showed a consistent profile with qd po regimens [&lt;ulink linkID="2021335" linkType="Reference"&gt;2021335&lt;/ulink&gt;]. Further clinical data were presented at the same conference. At dose 2, 5 and 10 mg, the change in AP with respect to dose response from baseline was - 21, - 33 and - 45%, respectively, in week 12 cohort. In week 26 cohort, the change in AP with respect to dose titration from baseline was - 43 (5 to 10 mg), - 45% (5 mg) and - 43% (10 mg). At 5 or 5 to 10 mg and 10 mg doses, responder rates were 68 and 79%, respectively. Overall,  seladelpar demonstrated  sustained  effects of  anti-cholestatic and anti-inflammatory activity [&lt;ulink linkID="2021312" linkType="Reference"&gt;2021312&lt;/ulink&gt;]. By August 2018, the 52-week data from the trial were expected in the fourth quarter of 2018 [&lt;ulink linkID="2062156" linkType="Reference"&gt;2062156&lt;/ulink&gt;]. In November 2018, it was expected that data from the ongoing study would be presented at   the AASLD's Liver Meeting in San Francisco, CA,  that month [&lt;ulink linkID="2091401" linkType="Reference"&gt;2091401&lt;/ulink&gt;]. Later that month, week 52 data from 34 patients were presented at the 69th AASLD Liver Meeting in San Francisco, CA. At week 52, the mean decreases in AP were -47 and -46% in the 5/10 and 10 mg groups, respectively. Â At 52 weeks, in the 5/10 and 10 mg groups, 59 and 71% of patients met the composite endpoint respectively; AP normalization occurred in 24 and 29% patients, respectively. In both the groups, median total bilirubin remained normal at week 52. Overall, seladelpar was generally safe, well tolerated and not associated with pruritus [&lt;ulink linkID="2092128" linkType="Reference"&gt;2092128&lt;/ulink&gt;] [&lt;ulink linkID="2094290" linkType="Reference"&gt;2094290&lt;/ulink&gt;]. Further data were presented at the same conference. . In patients with cirrhosis treated with seladelpar 5/10 and 10 mg adverse events occurring in &amp;gt;/= 20% of patients included pruritus, abdominal distension, fatigue, cough, dry mouth and abdominal tenderness. At week 26, in seladelpar 5/10 and 10 mg arms, the mean change in albumin were 5 and 4%, respectively, platelets were 14.1 and 5.8%, respectively, AST were 24 and 28%, respectively, GGT were 41 and 39%, respectively, visual analogue scale were 0 and -10, respectively [&lt;ulink linkID="2092212" linkType="Reference"&gt;2092212&lt;/ulink&gt;] [&lt;ulink linkID="2079038" linkType="Reference"&gt;2079038&lt;/ulink&gt;] [&lt;ulink linkID="2094290" linkType="Reference"&gt;2094290&lt;/ulink&gt;]. Further data were presented at the same conference. At week 26, in patients with cirrhosis receiving seladelpar (5/10 and 10 mg), the absolute change in visual analogue scale from baseline was -50 and -55%, respectively, the percentage of VAS change from baseline was -50 and -55%, respectively, the absolute change in 5-D itch from baseline was -1 and -2, respectively and the percentage change in 5-D itch change from baseline was -8 and -12%, respectively. There were no deaths or treatment-related serious AE reported [&lt;ulink linkID="2092165" linkType="Reference"&gt;2092165&lt;/ulink&gt;] [&lt;ulink linkID="2079038" linkType="Reference"&gt;2079038&lt;/ulink&gt;] [&lt;ulink linkID="2094290" linkType="Reference"&gt;2094290&lt;/ulink&gt;]. In April 2019, further data of 26 PBC patients with clinically diagnosed compensated cirrhosis were presented at the 2019 EASL International Liver Congress in Vienna, Austria. In 5/10 mg and 10 mg groups, mean decreases in AP were -36 and -43% at one year, respectively. After one year, AP &amp;lt; 1.67 x ULN was observed in all patients in 5/10 mg and three of five patients in 10 mg groups. After one year, the median decreases in ALT were -31 and -50%; and the median absolute changes in pruritus VAS were 0 and -25 in the 5/10 mg and 10 mg groups, respectively. Total bilirubin, platelets, albumin, and INR were found to remain stable. A total of six patients with cirrhosis experienced an serious adverse event, all unrelated to seladelpar [&lt;ulink linkID="2141966" linkType="Reference"&gt;2141966&lt;/ulink&gt;] [&lt;ulink linkID="2135330" linkType="Reference"&gt;2135330&lt;/ulink&gt;] [&lt;ulink linkID="2141205" linkType="Reference"&gt;2141205&lt;/ulink&gt;]. In May 2019, further clinical results were presented at the 2019 DDW in San Diego, CA.Out of 11 serious adverse events (AEs) reported, none were deemed to be related to seladelpar. None of the patients discontinued for transaminase elevations. Of the three discontinuations, one was due to grade 1 gastroesophageal reflux deemed related to seladelpar in non-cirrhotic patient and two were due to pneumonia and worsening of pruritus deemed unrelated.  Most common adverse events were pruritus, arthralgia, fatigue and urinary tract infections  [&lt;ulink linkID="2150697" linkType="Reference"&gt;2150697&lt;/ulink&gt;], [&lt;ulink linkID="2153781" linkType="Reference"&gt;2153781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, a 12-week, placebo-controlled, double blind, dose-ranging phase II trial (&lt;ulink linkID="246436" linkType="Protocol"&gt;NCT02609048&lt;/ulink&gt;; CB8025-21528)   was initiated in patients (expected n = 75) with PBC/cirrhosis in the US, UK, Canada, Germany and Poland. The trial was expected to be completed by the end of 2016 [&lt;ulink linkID="1712050" linkType="Reference"&gt;1712050&lt;/ulink&gt;], [&lt;ulink linkID="2030248" linkType="Reference"&gt;2030248&lt;/ulink&gt;]. In May 2016, the study was discontinued as the study met its objective of establishing proof-of-concept for seladelpar. The drug exhibited a potent anti-cholestatic effect. In the 26 patients enrolled, the mean decrease from baseline in ALP for the 50 and 200 mg dose groups were 57 and 62%, respectively. The responder rates for the placebo, 50 and 200 mg groups were 10, 67 and 100%, respectively. A lack of a dose response was seen. At that time, the company planned to conducted further studies using lower doses [&lt;ulink linkID="1767706" linkType="Reference"&gt;1767706&lt;/ulink&gt;]. In November 2016, the company planned to  initiate a follow-on phase II study  in primary biliary cirrhosis in the fourth quarter of 2016 [&lt;ulink linkID="1872623" linkType="Reference"&gt;1872623&lt;/ulink&gt;].In April 2017, further clinical data were presented in 35 patients at 52nd EASL International Liver Congress in Amsterdam, the Netherlands. There were no serious adverse events (AEs) reported during the treatment period. ALT elevation observed in 2 and 1 patients with 200 and 50 mg seladelpar (common terminology criteria for AEs  grade 3), respectively. No difference was observed in activity between the 50 and 200 mg dose groups [&lt;ulink linkID="1919606" linkType="Reference"&gt;1919606&lt;/ulink&gt;]. In August 2017, data from the randomised trial were published [&lt;ulink linkID="1953838" linkType="Reference"&gt;1953838&lt;/ulink&gt;], [&lt;ulink linkID="1953921" linkType="Reference"&gt;1953921&lt;/ulink&gt;]. In October 2017, interim analysis data were presented from an international, randomized, dose ranging, phase II study in patients with PBC were presented at the AASLD's Liver Meeting 2017 in Washington DC. Patients (n = 24) were randomized to receive seladelpar 5 and 10 mg (qd, po) and extension of dose adjustment of 5, 10 or 25 mg (n = 12) for 18 weeks. The mean change in alkaline phosphatase from baseline to week 12 was -39 and -45% at 5 and 10 mg doses, respectively. No statistical differences in least-square mean change in alkaline phosphatase from baseline to week 12 dose groups were reported. Nearly half of patients on 10 mg reported normal alkaline phosphatase at week 12 [&lt;ulink linkID="1973207" linkType="Reference"&gt;1973207&lt;/ulink&gt;], [&lt;ulink linkID="1969128" linkType="Reference"&gt;1969128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2015, a pre-IND meeting had been completed with the US FDA and a phase II study for PBC was expected to begin by the end of 2015 [&lt;ulink linkID="1685277" linkType="Reference"&gt;1685277&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-alcoholic steatohepatitis&lt;/subtitle&gt;In September 2017, the company was planning to initiate a phase II trial for NASH [&lt;ulink linkID="1960906" linkType="Reference"&gt;1960906&lt;/ulink&gt;]. In April 2018,  screening was initiated in  the phase IIb (&lt;ulink linkID="342452" linkType="Protocol"&gt;NCT03551522&lt;/ulink&gt;; CB8025-21730) study of seladelpar [&lt;ulink linkID="2031864" linkType="Reference"&gt;2031864&lt;/ulink&gt;], [&lt;ulink linkID="2134025" linkType="Reference"&gt;2134025&lt;/ulink&gt;]. In May 2018, a randomized, placebo-controlled, parallel-assigned, dose-ranging, proof-of-concept, phase IIb study was initiated in the US to evaluate seladelpar (10, 20 or 50 mg/day) versus placebo in patients (n = 181) with biopsy-proven NASH. The primary endpoint would be the change from baseline in liver fat content at 12 weeks measured by by MRI-PDFF [&lt;ulink linkID="2031714" linkType="Reference"&gt;2031714&lt;/ulink&gt;]. In November 2018, patient recruitment was one quarter ahead of schedule and it was expected that the trial would be fully enrolled in the first quarter of 2019  [&lt;ulink linkID="2091401" linkType="Reference"&gt;2091401&lt;/ulink&gt;]. In February 2019, enrollment was completed early with 181 patients. At that time, 12-week  topline data on changes in liver fat and key biochemical parameters were expected in 2Q19 [&lt;ulink linkID="2121011" linkType="Reference"&gt;2121011&lt;/ulink&gt;]. In June 2019, topline data were reported which showed that the trial did not meet its primary endpoint with a minimal reductions in liver fat for the seladelpar treatment that were not significant when compared to placebo [&lt;ulink linkID="2161555" linkType="Reference"&gt;2161555&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Homozygous familial hypercholesterolemia&lt;/subtitle&gt;In May 2016, the company planned to conduct another pilot phase II study in patients with HoFH   being treated with a PCSK9 inhibitor [&lt;ulink linkID="1761412" linkType="Reference"&gt;1761412&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, the company was planning to initiate a pilot phase II trial inÂ HoFH in Europe [&lt;ulink linkID="1611710" linkType="Reference"&gt;1611710&lt;/ulink&gt;]. In April 2015, an open label, dose-escalation,Â single-group-assigned, phase II trial (&lt;ulink linkID="232210" linkType="Protocol"&gt;NCT02472535&lt;/ulink&gt;; CB8025-21427)  was initiated in patients (n = 13) with HoFH in Europe, Canada and North America;  patients were expected to  initially receive  50 mg seladelpar, once daily that would  be increased to 100 mg and later to  200 mg eventually, over the course of 3 months. The primary endpoint was the reduction in serum LDL-C levels at any point from baseline to week 16. In February 2016, the trial was completed [&lt;ulink linkID="1653819" linkType="Reference"&gt;1653819&lt;/ulink&gt;], [&lt;ulink linkID="1750890" linkType="Reference"&gt;1750890&lt;/ulink&gt;]. In March 2016, top-line results from the 12 subjects treated in the trial were reported. Data demonstrated that seladelpar exhibited a greater than or equal to 30% decrease in three subjects (25%) and five subjects (42%) had a greater than or equal to 20% decrease, including one patient that was receptor negative, and seven (58%) had a greater than or equal to 15% decrease. Also, five subjects (42%) had a less than 15% decrease and the average maximum decrease in the study was 19%. In the second analysis, overall mean change for all 12 subjects was a decrease of 10% and eight of these subjects had a mean decrease in LDL-C of 16%, including 3 with a greater than 20% decrease [&lt;ulink linkID="1744679" linkType="Reference"&gt;1744679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Dyslipidemia&lt;/subtitle&gt;By April 2011, a phase II proof-of-concept study for dyslipidemia had been completed   [&lt;ulink linkID="1186675" linkType="Reference"&gt;1186675&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, Metabolex started a phase II trial (&lt;ulink linkID="17984" linkType="Protocol"&gt;NCT00701883&lt;/ulink&gt;; 70,961; M8025-20711) of seladelpar for dyslipidemia, insulin-resistance and obesity. The 8-week, placebo-controlled trial would enroll 180 overweight or obese subjects with high cholesterol and triglycerides, and will assess two dose levels of the drug with or without &lt;ulink linkID="2807" linkType="Drug"&gt;Lipitor&lt;/ulink&gt; (atorvastatin). The primary endpoint was Apo B-100 reduction and the secondary endpoints included LDL, HDL, triglyceride, glucose and insulin levels, and body weight and composition [&lt;ulink linkID="833111" linkType="Reference"&gt;833111&lt;/ulink&gt;]. In June 2008, Metabolex reported that enrollment of 180 	patients had been completed [&lt;ulink linkID="917186" linkType="Reference"&gt;917186&lt;/ulink&gt;]. In November 2008, results were presented at  the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Barcelona, Spain. Compared with placebo, a 30 and 20% reduction in triglycerides and LDL cholesterol, respectively, was observed in seladelpar alone-treated patients. Seladelpar also raised HDL cholesterol by 8% in the 50 mg cohort and by 12% in the 100 mg cohort. Furthermore, seladelpar decreased fasting insulin and glucose and significantly decreased GGT and alkaline phosphatase, suggestive of a reduction in liver inflammation [&lt;ulink linkID="964506" linkType="Reference"&gt;964506&lt;/ulink&gt;]. In July 2011, similar data were published. The drug was safe and generally well tolerated [&lt;ulink linkID="1222980" linkType="Reference"&gt;1222980&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Primary sclerosing cholangitis&lt;/subtitle&gt;In June 2019, the FDA approved an IND for the treatment of PSC. At that time, a randomized, placebo-controlled, dose-ranging phase II study to evaluate safety, tolerability and efficacy of seladelpar in patients (expected n = 100) with PSC was planned to initiate in 3Q19. The primary endpoint was relative change in alkaline phosphatase from baseline at 24 weeks [&lt;ulink linkID="2165814" linkType="Reference"&gt;2165814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2019, the drug was listed as being in phase I development for PSC [&lt;ulink linkID="2158123" linkType="Reference"&gt;2158123&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In November 2017, an open label, non-randomized phase I study (&lt;ulink linkID="322264" linkType="Protocol"&gt;NCT03369002&lt;/ulink&gt;; CB8025-11732) began in the US to evaluate the pharmacokinetics, safety and tolerability of po seladelpar in subjects (n = 32) with varying degrees of hepatic impairment (HI) and healthy matched control subjects with normal hepatic function. The trial completed in May 2018 [&lt;ulink linkID="2158229" linkType="Reference"&gt;2158229&lt;/ulink&gt;]. In April 2019, clinical clinical data were presented at the 2019 EASL International Liver Congress in Vienna, Austria. Mild HI subjects (n = 8) had no significant impact on seladelpar pharmacokinetics compared to controls (n = 8); seladelpar Cmax increased by 20%, seladelpar AUC increased by 10% and there was no change in t1/2. However, moderate and severe HI (n = 8 each) had an impact on seladelpar pharmacokinetics compared to controls; seladelpar Cmax increased to 5-fold, AUC increased to 2-fold and there was no change in t1/2. In subjects with varying degrees of HI, single dose of seladelpar was well tolerated [&lt;ulink linkID="2142051" linkType="Reference"&gt;2142051&lt;/ulink&gt;], [&lt;ulink linkID="2135330" linkType="Reference"&gt;2135330&lt;/ulink&gt;], [&lt;ulink linkID="2141205" linkType="Reference"&gt;2141205&lt;/ulink&gt;]. In May 2019, further data were presented at the 2019 DDW in San Diego, CA. Cmax was 71.9, 101, 398 and 379 ng/ml in normal subjects, patients with Child-Pugh A score, Child-Pugh B score and Child-Pugh C score, respectively; Tmax was 2, 1.5, 1 and 0.50 h; AUC (0 to t) was 668, 785, 1763 and 1530 h.ng/ml; AUC (0 to inf) was 705, 815, 1807 and 1616 h.ng/ml; t1/2 was 6.7, 6.2, 6.2 and 7.2 h; apparent total body clearance was 15.4, 14.3, 6.3 and 7.8 l/h and apparent volume of distribution was 141, 120, 54.6 and 78.7 l, respectively [&lt;ulink linkID="2150740" linkType="Reference"&gt;2150740&lt;/ulink&gt;], [&lt;ulink linkID="2149547" linkType="Reference"&gt;2149547&lt;/ulink&gt;], [&lt;ulink linkID="2153781" linkType="Reference"&gt;2153781&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By April 2015, five phase I studies had been completed [&lt;ulink linkID="1653999" linkType="Reference"&gt;1653999&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In April 2019, preclinical data were presented at the 2019 EASL International Liver Congress in Vienna, Austria. In male C57BL/6J mice treated with seladelpar alone or seladelpar + liraglutide and seladelpar + selonsertib combinations, robust reductions in liver fibrosis as determined by hydroxyproline content were observed with combination treatments compared to NASH vehicle and the other single agents (p &amp;lt; 0.0001). Similar results were observed in morphometric analysis of picrosirius red staining. When compared to NASH vehicle, seladelpar, liraglutide and the seladelpar + liraglutide and seladelpar + selonsertib combinations produced significant reductions in Col 1 alpha1 mRNA and other mRNA indices of fibrosis (p &amp;lt; 0.0001)    [&lt;ulink linkID="2141864" linkType="Reference"&gt;2141864&lt;/ulink&gt;], [&lt;ulink linkID="2135330" linkType="Reference"&gt;2135330&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, preclinical data were presented at 53rd EASL International Liver Congress in Paris, France. There was no accumulation reported in any tissue in a rat mass balance study; the radioactivity was limited to the gastrointestinal tract and other excretory organs after 24 h. In bile duct annulated rats (male and female Sprague-Dawley rats), the majority of radioactivity was found in the bile in the first 24 h after treated with (14C) seladelpar (15 mg/kg); the main route of elimination was fecal excretion [&lt;ulink linkID="2021335" linkType="Reference"&gt;2021335&lt;/ulink&gt;]. Â &lt;/para&gt;&lt;para&gt;In July 2017,  preclinical data were published. Seladelpar normalized hyperglycemia, hyperinsulinemia, and glucose intolerance. Seladelpar reduced ALT by 50%, normalized serum lipids and hepatic levels of free cholesterol and other lipotoxic lipids in diabetic, obese mouse model of NASH. Seladelpar treated mice also experienced a reversal of NASH pathology, with significant improvement in liver fibrosis, reductions in inflammation and a complete abrogation of hepatocyte ballooning [&lt;ulink linkID="1980035" linkType="Reference"&gt;1980035&lt;/ulink&gt;], [&lt;ulink linkID="1981007" linkType="Reference"&gt;1981007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were presented at the AASLD's Liver Meeting 2016 in Boston, MA. MBX-8025 improved glucose tolerance and reversed diabetes, atherogenic dyslipidemia, hepatic lipid storage including lipotoxic lipids, and NASH pathology in atherogenic diet-fed diabetic mice [&lt;ulink linkID="1872930" linkType="Reference"&gt;1872930&lt;/ulink&gt;], [&lt;ulink linkID="1865460" linkType="Reference"&gt;1865460&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2015, three-month toxicology studies in rodents alone and in combination with &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin&lt;/ulink&gt;, and in monkeys had been completed, along with the 2-year carcinogenicity studies in mice and rats and data were reported. Data demonstrated increased peripheral oxidation of fatty acids leading to reduced levels of triglycerides (TGs) and low-density lipoprotein (LDL).  Seladelpar also  inhibited fat mass accumulation, resulting in attenuation of body weight gain in rodent models of obesity [&lt;ulink linkID="1653999" linkType="Reference"&gt;1653999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, preclinical data were reported from a study conducted in watanabe-heritable hyperlipidemic (WHHL) rabbit model of HoFH. In the study, five WHHL rabbits were dosed by sc administration of seladelpar (30 mg/kg) once daily for three weeks, followed by a four-week washout period. Data demonstrated that treatment with seladelpar resulted in changes from baseline in mean LDL-C of -33, -45 and -42% at weeks 1, 2 and 3, respectively. An absolute decrease in LDL-C (114-302 mg/dl; p &amp;lt; 0.01 for all changes versus baseline) was observed in all the rabbits. In addition, the LDL-C lowering effect of seladelpar was completely reversed after a washout period of 4 weeks [&lt;ulink linkID="1629434" linkType="Reference"&gt;1629434&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-12T00:00:00.000Z</StatusDate><Source id="1996771" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-12T00:00:00.000Z</StatusDate><Source id="1996771" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-12T00:00:00.000Z</StatusDate><Source id="1996771" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-08T00:00:00.000Z</StatusDate><Source id="2031714" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2477">Primary sclerosing cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-02T00:00:00.000Z</StatusDate><Source id="2158123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3294">Metabolic syndrome X</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17580">Ortho-McNeil Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-26T00:00:00.000Z</StatusDate><Source id="675598" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1712050" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1712050" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-28T00:00:00.000Z</StatusDate><Source id="1629434" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-23T00:00:00.000Z</StatusDate><Source id="1653819" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-30T00:00:00.000Z</StatusDate><Source id="1750890" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-23T00:00:00.000Z</StatusDate><Source id="1653819" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-09-25T00:00:00.000Z</StatusDate><Source id="833111" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3294">Metabolic syndrome X</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-27T00:00:00.000Z</StatusDate><Source id="1186675" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-11T00:00:00.000Z</StatusDate><Source id="1960906" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1995">Primary biliary cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1712050" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17580">Ortho-McNeil Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-26T00:00:00.000Z</StatusDate><Source id="675598" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-26T00:00:00.000Z</StatusDate><Source id="675598" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-26T00:00:00.000Z</StatusDate><Source id="675598" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18199">CymaBay Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-27T00:00:00.000Z</StatusDate><Source id="833111" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1995">Primary biliary cholangitis</Indication><AwardedIndication>Treatment of early stage PBC in combination with ursodeoxycholic acid (UDCA)  in adult patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-15T00:00:00.000Z</MileStoneDate><Source id="2120303" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1995">Primary biliary cholangitis</Indication><AwardedIndication>Treatment of primary biliary cholangitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-16T00:00:00.000Z</MileStoneDate><Source id="1987727" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1995">Primary biliary cholangitis</Indication><AwardedIndication>Treatment of primary biliary cholangitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-07T00:00:00.000Z</MileStoneDate><Source id="1960906" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1995">Primary biliary cholangitis</Indication><AwardedIndication>Treatment of primary biliary cholangitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-07T00:00:00.000Z</MileStoneDate><Source id="1871725" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication>Treatment of patients with Frederickson Type I or V hyperlipoproteinemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-15T00:00:00.000Z</MileStoneDate><Source id="1652799" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="584">Lipid metabolism disorder</Indication><AwardedIndication>Treatment of patients with Frederickson Type I or V hyperlipoproteinemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-15T00:00:00.000Z</MileStoneDate><Source id="1652799" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3204">Familial hypercholesterolemia</Indication><AwardedIndication>Treatment of homozygous familial hypercholesterolemia (HoFH)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-18T00:00:00.000Z</MileStoneDate><Source id="1644945" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3204">Familial hypercholesterolemia</Indication><AwardedIndication>Treatment of homozygous familial hypercholesterolemia (HoFH)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-18T00:00:00.000Z</MileStoneDate><Source id="1644945" type="PR"></Source></Row><Row><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation><OwnerCompany id="18199">CymaBay Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1995">Primary biliary cholangitis</Indication><AwardedIndication>Treatment of Primary Biliary Cholangitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-13T00:00:00.000Z</MileStoneDate><Source id="1865233" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01595"><Name>PPAR delta</Name><SwissprotNumbers><Swissprot>P35396</Swissprot><Swissprot>P37233</Swissprot><Swissprot>Q03181</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2165814" linkType="reference" linkID="2165814"&gt;2165814&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1087639">Histoindex Pte Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18199">CymaBay Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(c(c2)C)OCC(=O)O</Smiles><Smiles>CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(c(c2)C)OCC(=O)O.C(CCN)C[C@@H](C(=O)O)N.O.O</Smiles></StructureSmiles><Deals><Deal id="108994" title="Ortho-McNeil and Metabolex to codevelop Metabolex's MBX-2044 and metaglidasen, and McNeil's RWJ-800025"></Deal><Deal id="247018" title="Histoindex to evaluate effficacy of CymaBay's seladelpar for NASH using Genesis 200 imaging technology     "></Deal></Deals><PatentFamilies><PatentFamily id="1708665" number="WO-2010045361" title="Methods of reducing small, dense LDL particles"></PatentFamily><PatentFamily id="1736852" number="WO-2007033231" title="Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives"></PatentFamily><PatentFamily id="1826461" number="WO-2005042478" title="4-((Phenoxyalkyl)thio-phenoxyacetic acids and analogs"></PatentFamily><PatentFamily id="3035739" number="WO-2015143178" title="Treatment of intrahepatic cholestatic diseases"></PatentFamily><PatentFamily id="3050714" number="WO-2015157697" title="Treatment of NAFLD and NASH"></PatentFamily><PatentFamily id="3855818" number="WO-2017200715" title="Treatment of severe hyperlipidemia"></PatentFamily><PatentFamily id="3864205" number="WO-2017209865" title="Treatment of intrahepatic cholestatic diseases"></PatentFamily><PatentFamily id="4012257" number="WO-2015200580" title="Treatment of severe hypertriglyceridemia"></PatentFamily><PatentFamily id="4389117" number="US-20190038581" title="Treatment of intrahepatic cholestatic diseases"></PatentFamily><PatentFamily id="4455594" number="WO-2019067373" title="Treatment of cholestatic pruritus"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CymaBay Therapeutics Inc" id="18199"></CompanyLink><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>